research published 2021-06-01 · by Ablin JN, Aloush V, Amital H, Atzeni F, Batticciotto A, Bazzichi L, Buskila D, Cassisi G, Choy EH, Coaccioli S, Da Silva JAP, Di Carlo M, Di Franco M, Giorgi V, Gorla R, Häuser W, Kosek E, Mannerkorpi K, Morlion B, Øien Forseth KM, Perrot S, Polati E, Salaffi F, Sarzi-Puttini P, Schweiger V, Torta R, Varrassi G

Clinical and experimental rheumatology · 2021 May-Jun

PubMed #34001303

Abstract

Fibromyalgia syndrome is one of the most common causes of chronic widespread pain, but pain accompanies a wide range of ancillary symptoms. To date, its aetiopathogenesis remains elusive, and diagnosis is exquisitely clinical, due to the lack of biomarkers or specific laboratory alterations in fibromyalgia patients. This position paper has the purpose to summarise the current scientific knowledge and expert opinions about the main controversies regarding fibromyalgia syndrome, namely: (i) fibromyalgia definition and why it is still not recognised in many countries as a distinct clinical entity; (ii) fibromyalgia severity and how to evaluate treatment outcome; (iii) how to treat fibromyalgia and which is a correct approach to fibromyalgia patients.

Neurotransmitters

None linked yet.

Related

Community votes: 0

Ratings (0): Breadth — · Depth — · Enjoyment — · Usefulness —

Community

Log in to rate and share your notes.

No contributions yet.